Metaplasia Myelofibrosis

Authors

  • LENA WIJAYANINGRUM Faculty of Medicine, Hangtuah University
  • I DEWA MADE WIDI HERSANA Medical Faculty of Hang Tuah University / Hemato Oncology Subdepartment, of Navy Hospital Surabaya
  • I KETUT TIRKA NANDAKA Faculty of Medicine, Hangtuah University

DOI:

https://doi.org/10.30649/htmj.v23i1.662

Keywords:

Myelofibrosis with myeloid metaplasia, JAK2 V617F mutation, Splenomegaly, Ruxolitinib Jakavi

Abstract

Background: Myelofibrosis with myeloid metaplasia is a rare myeloproliferative disorder. Epidemiological data on the incidence of Myelofibrosis with myeloid metaplasia are still lacking. In Goteborg, Sweden, from 1983 to 1992, the incidence of the disease was retrospectively calculated at 0.4 per 100,000 population. In population- based leukemia data in the UK, the incidence of Myelofibrosis with myeloid metaplasia is estimated to be 0.73 per 100,000 person-years in men and 0.40 per 100,000 person-years in women. It is estimated that there are 230 new cases each year in England and Wales, 330 in Italy, and 1,600 in the United States. No medical therapies have been shown to be effective against the overall survival of patients. The prognosis of myelofibrosis with myeloid metaplasia varies widely. For this reason, it is necessary to report cases of Myelofibrosis Myeloid Metaplasia Methode: Descriptive research, in the form of case reports of patients with myelofibrosis metaplasia, with data obtained from primary data anamnesa and direct physical examination of patients and secondary data

 

from medical records, the results of examinations of doctors at RSPAL Dr Ramelan Surabaya 2022-2024.

Results: Since 13 December 2022 until this date 3 May 2024 (17 months).Patient with a diagnosis of Primary Myelofibrosis and high Uric Acid after undergoing therapy with jakavi 15 mg 1x1. Allopurinol 300mg 1x1 and Nabic 3x1. Experienced improvement in complaints of increased appetite. Resting at night there are no complaints. Activity such as walking is not easily tired, mass in the abdomen that does not cause pain. On physical examination, there was an increase in body weight from 50 kg to 55 kg and still found S IV splenomegaly, from the haematological examination there was a decrease in platelets 136.00 (10^3µL) which was previously 203.00 (10^3µL). Uric acid improved from 10.8 mg/dl to 7.7 mg/dl.

Conclusion: Jakavi is a drug containing ruxolitinib that can treat splenomegaly or disease-related symptoms in adult patients with myelofibrosis.

Keywords: Myelofibrosis Metaplasia.Splenomegaly.Jakavi

References

Barosi, G., 2003. Myelofibrosis with myeloid metaplasia. Hematology/Oncology Clinics of North America, 17(5), pp.1211–1226.

Chagraoui, H., Wendling, F. and Vainchenker, W., 2006. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models. Best Practice and Research: Clinical Haematology, 19(3), pp.399–412.

Dingli, D., Mesa, R.A. and Tefferi, A., 2004. Myelofibrosis with myeloid metaplasia: New developments in pathogenesis and treatment. Internal Medicine, 43(7), pp.540–547.

Jakavi. (2021). Diakses pada 19 Juni 2024 dari https://www.klikdokter.com/obat/obat-kemoterapi/jakavi

Mesa, R.A., Barosi, G., Cervantes, F., Reilly, J.T. and Tefferi, A., 2006. Myelofibrosis with myeloid metaplasia: Disease overview and non- transplant treatment options. Best Practice and Research: Clinical Haematology, 19(3), pp.495–517.

Sussman, J.D. and Davies-Jones, G.A.B., 2014. Neurologic Manifestations of Hematologic Disorders. [online] Aminoff’s Neurology and General Medicine: Fifth Edition. Elsevier Inc. Available at:<http://dx.doi.org/10.1016/B978-0-12407710-2.00025-4>.

Steensma DP, Tefferi A. Myelofibrosis with Myeloid Metaplasia. In: Kufe DW, Pollock

RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1

Published

2025-11-28

How to Cite

WIJAYANINGRUM, L., I DEWA MADE WIDI HERSANA, & I KETUT TIRKA NANDAKA. (2025). Metaplasia Myelofibrosis . Hang Tuah Medical Journal, 23(1), 111–124. https://doi.org/10.30649/htmj.v23i1.662